BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37918263)

  • 21. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Voutsadakis IA
    Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
    [No Abstract]   [Full Text] [Related]  

  • 22. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
    Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
    J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of association between HLA-E polymorphisms and transitional cell carcinoma of the bladder.
    Veiga-Castelli LC; de Paula Cruz AS; Inácio MM; Mendes-Junior CT; Vianello-Brondani R; Moreau P; Castelli EC; Donadi EA
    Tissue Antigens; 2013 Sep; 82(3):197-200. PubMed ID: 23786553
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
    Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
    Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of replication protein A3 is associated with unfavorable outcome in bladder urothelial carcinoma.
    Sun D; Zhang K; Fu Q; Zhang H; Liu S; Wang H; Xu Z; Wang J
    J Cancer Res Ther; 2021 Jul; 17(3):771-776. PubMed ID: 34269312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.
    Datar IJ; Hauc SC; Desai S; Gianino N; Henick B; Liu Y; Syrigos K; Rimm DL; Kavathas P; Ferrone S; Schalper KA
    Clin Cancer Res; 2021 May; 27(10):2837-2847. PubMed ID: 33602682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
    Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
    Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
    BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of prognostic and therapeutic value of CC chemokines in Urothelial bladder cancer: evidence from comprehensive bioinformatic analysis.
    Li Y; Chen X; Li D; Yang Z; Bai Y; Hu S; Liu Z; Gu J; Zhang X
    BMC Urol; 2021 Dec; 21(1):173. PubMed ID: 34893045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of Protein-related Risk Score Model in Bladder Urothelial Carcinoma.
    Luo Q; Zhang X
    Biomed Res Int; 2020; 2020():7147824. PubMed ID: 32802870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer.
    Bahls L; Yamakawa R; Zanão K; Alfieri D; Flauzino T; Delongui F; de Abreu A; Souza R; Gimenes F; Reiche E; Borelli S; Consolaro M
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-G expression in transitional bladder carcinoma. Relationship with tumor invasion level and patient survival: Experience in a public hospital in Argentina.
    Moavro DE; Andrini L; Iribarne A; Colaci P; García M
    Hum Immunol; 2023 Aug; 84(8):423-427. PubMed ID: 37069040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
    Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Yang F; Zhou Q; Meng L; Xing N
    Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates.
    Arndt MF; Koohestani DM; Chobrutskiy BI; Mihyu MM; Diaz M; Gozlan EC; Yeagley M; Zaman S; Roca AM; Blanck G
    Hum Immunol; 2020 Dec; 81(12):692-696. PubMed ID: 32950267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates.
    Callahan BM; Tong WL; Blanck G
    Immunol Res; 2018 Apr; 66(2):219-223. PubMed ID: 29594966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.